A phase I trial to determine Givastomig in newly diagnosed (frontline treatment) gastric cancer and esophageal cancer in combination with chemotherapy and a checkpoint inhibitor
Latest Information Update: 10 Jun 2025
At a glance
- Drugs Givastomig (Primary) ; Nivolumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors I-MAB Biopharma
Most Recent Events
- 03 Jun 2025 According to an I-Mab media release, the trial has been selected for a Mini Oral presentation at the ESMO GI Cancers Congress, scheduled for July 2, 2025.
- 15 May 2025 According to an I-Mab media release, dose escalation combination data on U.S. patients will be presented at the European Society of Medical Oncology Gastrointestinal Cancers Congress 2025, being held July 2-5 in Barcelona, Spain.
- 30 Apr 2025 According to an I-Mab media release, the company announced that an abstract for a combination study of givastomig plus nivolumab and chemotherapy has been accepted for a mini-oral presentation at the ESMO Gastrointestinal Cancers Congress 2025, which will be held July 2-5 in Barcelona, Spain.